Furthermore, the increased fibronectin abundance induced by either TAZ knockdown or TGF-β treatment (possibly the mesenchymal characteristics of cancer cells) did not contribute to breast cancer cell migration, as TAZ knockdown decreased cell migration, while TGF-β treatment had the opposite effect despite the presence of TAZ knockdown (Figure 3). The gene discussed is FN1; the disease is breast cancer.